Last reviewed · How we verify

NCT04070612: BIOCEREVANCE

National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia.

Completed Last updated 28 August 2019
What this trial tests

trial testing Blood sample in Cytopenia in 122 participants. Completed in 8 June 2012.

Timeline
4 April 2007
Primary endpoint
8 June 2012
8 June 2012

Quick facts

Lead sponsorUniversity Hospital, Bordeaux
StatusCompleted
Study typeOBSERVATIONAL
Enrollment122
Start date4 April 2007
Primary completion8 June 2012
Estimated completion8 June 2012

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bordeaux

Who can join

Under 18, any sex, with Cytopenia or Autoimmune Haemolytic Anaemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to study prospectively the clinical and paraclinical evolution and prognostic factors of autoimmune haemolytic anemias, Evans syndromes and chronic immunological thrombocytopenic purpura of children in France.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

Other recruiting trials for Cytopenia

Currently open trials in the same condition.

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04070612.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing